🥊In an exclusive and insightful interview, UFC Hall of Famer and Brazilian Jiu-Jitsu Blackbelt, Royce Gracie, shares his personal journey of overcoming joint pain and how Cytonics’ revolutionary A2M therapy has transformed his life.
🥊❓The Struggle and the Search for Relief
Royce Gracie, a name synonymous with resilience and strength in the martial arts world, faced a formidable opponent outside the ring – debilitating joint pain. Despite his remarkable career and achievements, Gracie found himself grappling with a challenge that many athletes and individuals face as they age.
🔄💊 Turning Point with Cytonics A2M Therapy
In his pursuit of relief, Gracie discovered Cytonics’ Autologous Protease Inhibitor Concentrate (APIC) therapy, a cutting-edge treatment that harnesses the power of Alpha-2-Macroglobulin (A2M). Unlike traditional treatments that offered only temporary solutions, Cytonics’ APIC-A2M therapy presented a promising, long-term approach.
“Before the treatment, my mobility was severely hindered. I couldn’t train or enjoy everyday activities without pain,” says Gracie. “But after undergoing the APIC therapy, I felt a significant improvement. It’s not just about managing pain; it’s about reclaiming your life.”
~ Royce Gracie, UFC Legend
💡🔬 A Testament to Innovation
The clinical and commercial success of APIC is more than just a money generator… it is a testament to the power of A2M as an effective treatment for osteoarthritis. It is clear cut evidence that A2M can actually stop cartilage degradation. Therefore, it stands to reason that our novel A2M variant, CYT-108, may be an even more effective therapy as well. That simple logic significantly de-risks the development of CYT-108, and gives us great confidence that we will see positive results in our upcoming human clinical trials.
🚀🏥 An Opportunity to Invest in the Future of Healthcare
Royce Gracie’s endorsement of Cytonics’ A2M therapy is more than just a success story; it’s a call to action. As we embark on our first-in-human Phase 1 clinical trial later this year, we invite new investors to be part of a revolutionary journey in healthcare. Together, we can eradicate osteoarthritis once and for all, and change the lives of millions of suffering people worldwide.
Ready to become a shareholder? Visit invest.cytonics.com.
This communication may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.
Leave a Reply